Covira Surgical engages in the development of drugs that modulate the biological activity of the gut microbiome's resident bacteria. It is based on the work of Dr. John Alverdy, MD, a world authority on the molecular basis of post-surgical infections. Covira’s platform technology generated a lead asset (CS-0003) that modulates bacterial